scholarly journals Long-term results with vagus nerve stimulation in children with pharmacoresistant epilepsy

Seizure ◽  
2006 ◽  
Vol 15 (7) ◽  
pp. 491-503 ◽  
Author(s):  
Andreas V. Alexopoulos ◽  
Prakash Kotagal ◽  
Tobias Loddenkemper ◽  
Jeffrey Hammel ◽  
William E. Bingaman
Seizure ◽  
2018 ◽  
Vol 59 ◽  
pp. 41-47 ◽  
Author(s):  
Jan Chrastina ◽  
Zdeněk Novák ◽  
Tomáš Zeman ◽  
Jitka Kočvarová ◽  
Martin Pail ◽  
...  

2012 ◽  
Vol 28 (4) ◽  
pp. 621-628 ◽  
Author(s):  
Beata Majkowska-Zwolińska ◽  
Piotr Zwoliński ◽  
Marcin Roszkowski ◽  
Krzysztof Drabik

Seizure ◽  
1999 ◽  
Vol 8 (6) ◽  
pp. 328-334 ◽  
Author(s):  
K Vonck ◽  
P Boon ◽  
M D’Havé ◽  
T Vandekerckhove ◽  
S O’Connor ◽  
...  

2005 ◽  
Vol 32 (S 4) ◽  
Author(s):  
J Baldauf ◽  
M Ahrens ◽  
K Rieck ◽  
J.U Müller ◽  
H.W.S Schroeder ◽  
...  

2014 ◽  
Vol 7 (6) ◽  
pp. 914-916 ◽  
Author(s):  
Didier Clarençon ◽  
Sonia Pellissier ◽  
Valérie Sinniger ◽  
Astrid Kibleur ◽  
Dominique Hoffman ◽  
...  

2019 ◽  
Vol 20 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Laura Pérez-Carbonell ◽  
Howard Faulkner ◽  
Sean Higgins ◽  
Michalis Koutroumanidis ◽  
Guy Leschziner

Vagus nerve stimulation (VNS) is a neuromodulatory therapeutic option for drug-resistant epilepsy. In randomised controlled trials, VNS implantation has resulted in over 50% reduction in seizure frequency in 26%–40% of patients within 1 year. Long-term uncontrolled studies suggest better responses to VNS over time; however, the assessment of other potential predictive factors has led to contradictory results. Although initially designed for managing focal seizures, its use has been extended to other forms of drug-resistant epilepsy. In this review, we discuss the evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy. We also include practical guidance for the approach to and the management of patients with VNS in situ.


Sign in / Sign up

Export Citation Format

Share Document